RT Journal Article
T1 Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions.
A1 Sánchez-Varo, Raquel María
A1 López-Salas, Alexander
A1 Rasiel, Beltran-Casanueva
A1 Díaz-Sánchez, Estela
A1 Álvarez-Contino, José Erik
A1 Barbancho-Fernández, Miguel Ángel
A1 Serrano-Castro, Pedro Jesús
A1 Fuxe, Kjell
A1 Borroto Escuela, Dasiel Óscar
A1 García-Casares, Natalia
A1 Narváez-Peláez, Manuel
K1 Neurobiología del desarrollo
K1 Sistema nervioso - Degeneración
K1 Sistema nervioso - Regeneración
AB Background: Spatial memory deficits and reduced neuronal survival contribute to cognitive decline seen in the aging process. Current treatments are limited, emphasizing the need for innovative therapeutic strategies. This research explored the combined effects of intranasally co‑administered galanin receptor 2 (GALR2) and neuropeptide Y1 receptor (NPY1R) agonists, recognized for their neural benefits, on spatial memory, neuronal survival, and differentiation in adult rats. After intranasal co‑delivery of the GALR2 agonist M1145 and a NPY1R agonist to adult rats, spatial memory was tested with the object‑in‑place task 3 weeks later. We examined neuronal survival and differentiation by assessing BrdUIR profiles and doublecortin (DCX) labeled cells, respectively. We also used the GALR2 antagonist M871 to confirm GALR2’s crucial role in promoting cell growth. Results: Co‑administration improved spatial memory and increased the survival rate of mature neurons. The positive effect of GALR2 in cell proliferation was confirmed by the nullifying effects of its antagonist. The treatment boosted DCX‑labeled newborn neurons and altered dendritic morphology, increasing cells with mature dendrites. Conclusions: Our results show that intranasal co‑delivery of GALR2 and NPY1R agonists improves spatial memory, boosts neuronal survival, and influences neuronal differentiation in adult rats. The significant role of GALR2 is emphasized, suggesting new potential therapeutic strategies for cognitive decline.
PB Springer Nature
YR 2024
FD 2024-03-28
LK https://hdl.handle.net/10630/31811
UL https://hdl.handle.net/10630/31811
LA eng
NO Sánchez-Varo R, López-Salas A, Beltran-Casanueva R, Díaz-Sánchez E, Alvarez-Contino JE, Barbancho-Fernández MA, Serrano-Castro P, Fuxe K, Borroto-Escuela DO, García-Casares N, Narváez M. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions. Behav Brain Funct. 2024 Mar 28;20(1):6. doi: 10.1186/s12993-024-00230-5. PMID: 38549164; PMCID: PMC10976774.
NO UMA18‑FEDERJA‑100 and ProyExcel_00613, Junta de Andalucía, Spain, to MN. Funding for open access charge: Universidad de Málaga.Cátedra Imbrain: Neurociencia integrada y bienestar to MN.The Swedish Medical Research Council, Sweden (62X‑00715‑50‑3) to KF, by Stiftelsen Olle Engkvist Byggmästare to KF, and by Hjärnfonden, Sweden (F02018‑0286), Hjärnfonden, Sweden (F02019‑0296), EMERGIA 2020‑39318 (Plan Andaluz de Investigación, Desarrollo e Innovación 2020), and CONSOLIDACION INVESTIGADORA (CNS2022‑136008, Programa Estatal para Desarrollar, Atraer y Retener Talento, del Plan Estatal de Investigación Científica, Técnica y de Innovación 20212023) and Karolinska Institutet Forskningsstiftelser, Sweden, to D.B.‑E.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026